Veracyte, Inc.

As of June 30, 2026, Veracyte, Inc. carries a market capitalization of 4.13B, placing it among publicly traded companies globally. Its enterprise value stands at 3.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Veracyte, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Veracyte, Inc. has 80.36M shares outstanding.

As of June 30, 2026, Veracyte, Inc. trades at a trailing price-to-earnings ratio of 40.70. The price-to-sales ratio is 8.29, and the price-to-book ratio stands at 3.40.

As of June 30, 2026, Veracyte, Inc. trades at an EV/EBITDA multiple of 33.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 40.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Veracyte, Inc. trades at an EV/FCF ratio of 25.75, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.74B versus a market cap of 4.13B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Veracyte, Inc. maintains a current ratio of 9.16, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Veracyte, Inc. posted a return on equity (ROE) of 8.77, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.48, useful for judging operating efficiency across full business cycles. The company generates approximately 636,880.63 in revenue per employee across its workforce of 772.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.67 indicates how many times Veracyte, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Veracyte, Inc. recorded 1.35M in income tax expense. That works out to an effective tax rate of 1.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 101.55M, leaving 100.21M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Veracyte, Inc.'s stock has gained approximately 36.17% over the past 52 weeks. The 50-day moving average sits at 38.00, while the 200-day moving average is 37.10.

Over the twelve months ended June 30, 2026, Veracyte, Inc. generated 491.83M in revenue and converted that into 100.21M in net income, yielding earnings per share of 1.24. EBITDA reached 110.81M, while operating income came in at 95.10M.

As of June 30, 2026, Veracyte, Inc. holds 424.72M in cash and equivalents against 35.11M in total debt, resulting in a net debt position of -262.17M. Total book value stands at 1.22B, with working capital of 448.19M providing operational flexibility.

Veracyte, Inc. produced 156.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.85M in capital expenditures, free cash flow totaled 145.29M - equivalent to 1.83 per share.

Over the twelve months ended June 30, 2026, Veracyte, Inc. posted a gross margin of 71.71, reflecting its pricing power and cost economics. The operating margin of 19.34 and net profit margin of 20.37 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.48, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.01, meaning Veracyte, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Veracyte, Inc. has an Altman Z-Score of 30.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.